Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Impact of certolizumab pegol on patient-reported outcomes in rheumatoid arthritis and correlation with clinical measures of disease activity.

Pope J, Bingham CO 3rd, Fleischmann RM, Dougados M, Massarotti EM, Wollenhaupt J, Duncan B, Coteur G, Weinblatt ME.

Arthritis Res Ther. 2015 Nov 27;17:343. doi: 10.1186/s13075-015-0849-1.

2.

Are patient-reported outcome instruments for ankylosing spondylitis fit for purpose for the axial spondyloarthritis patient? A qualitative and psychometric analysis.

van Tubergen A, Black PM, Coteur G.

Rheumatology (Oxford). 2015 Oct;54(10):1842-51. doi: 10.1093/rheumatology/kev125. Epub 2015 May 21. Review.

PMID:
26001635
3.

Impact of Certolizumab Pegol on Patient-Reported Outcomes in Patients With Axial Spondyloarthritis.

Sieper J, Kivitz A, van Tubergen A, Deodhar A, Coteur G, Woltering F, Landewé R.

Arthritis Care Res (Hoboken). 2015 Oct;67(10):1475-80. doi: 10.1002/acr.22594.

4.

Re-Validation of the Self-Injection Assessment Questionnaire© (Siaqv2.0©) in Rheumatoid Arthritis Patients on Certolizumab Pegol Treatment.

Coteur G.

Value Health. 2014 Nov;17(7):A570. doi: 10.1016/j.jval.2014.08.1904. Epub 2014 Oct 26. No abstract available.

5.

Validity And Responsiveness Of The Bristol Rheumatoid Arthritis Fatigue Multidimensional Questionnaire (BRAF-MDQ) In A Randomized Controlled Clinical Trial.

Kirwan J, Coteur G, Dures E, Nicklin J, Bryson J, Hewlett S.

Value Health. 2014 Nov;17(7):A568-9. doi: 10.1016/j.jval.2014.08.1896. Epub 2014 Oct 26. No abstract available.

6.

Effect of certolizumab pegol on multiple facets of psoriatic arthritis as reported by patients: 24-week patient-reported outcome results of a phase III, multicenter study.

Gladman D, Fleischmann R, Coteur G, Woltering F, Mease PJ.

Arthritis Care Res (Hoboken). 2014 Jul;66(7):1085-92. doi: 10.1002/acr.22256.

7.

Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study.

Landewé R, Braun J, Deodhar A, Dougados M, Maksymowych WP, Mease PJ, Reveille JD, Rudwaleit M, van der Heijde D, Stach C, Hoepken B, Fichtner A, Coteur G, de Longueville M, Sieper J.

Ann Rheum Dis. 2014 Jan;73(1):39-47. doi: 10.1136/annrheumdis-2013-204231. Epub 2013 Sep 6.

8.

Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab' certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension.

Reich K, Ortonne JP, Gottlieb AB, Terpstra IJ, Coteur G, Tasset C, Mease P.

Br J Dermatol. 2012 Jul;167(1):180-90. doi: 10.1111/j.1365-2133.2012.10941.x. Epub 2012 Jun 11.

PMID:
22413944
9.

Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial.

Sandborn WJ, Schreiber S, Feagan BG, Rutgeerts P, Younes ZH, Bloomfield R, Coteur G, Guzman JP, D'Haens GR.

Clin Gastroenterol Hepatol. 2011 Aug;9(8):670-678.e3. doi: 10.1016/j.cgh.2011.04.031. Epub 2011 May 13.

PMID:
21642014
10.

Evaluation of a daily practice composite score for the assessment of Crohn's disease: the treatment impact of certolizumab pegol.

Feagan BG, Hanauer SB, Coteur G, Schreiber S.

Aliment Pharmacol Ther. 2011 May;33(10):1143-51. doi: 10.1111/j.1365-2036.2011.04636.x. Epub 2011 Mar 28.

11.

Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trial.

Strand V, Smolen JS, van Vollenhoven RF, Mease P, Burmester GR, Hiepe F, Khanna D, Nikaï E, Coteur G, Schiff M.

Ann Rheum Dis. 2011 Jun;70(6):996-1002. doi: 10.1136/ard.2010.143586. Epub 2011 Mar 17.

12.

Rapid improvement in the signs and symptoms of rheumatoid arthritis following certolizumab pegol treatment predicts better longterm outcomes: post-hoc analysis of a randomized controlled trial.

Keystone EC, Curtis JR, Fleischmann RM, Furst DE, Khanna D, Smolen JS, Mease PJ, Schiff MH, Coteur G, Davies O, Combe B.

J Rheumatol. 2011 Jun;38(6):990-6. doi: 10.3899/jrheum.100935. Epub 2011 Mar 1.

13.
14.

Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn's disease with prior loss of response to infliximab.

Feagan BG, Sandborn WJ, Wolf DC, Coteur G, Purcaru O, Brabant Y, Rutgeerts PJ.

Aliment Pharmacol Ther. 2011 Mar;33(5):541-50. doi: 10.1111/j.1365-2036.2010.04568.x. Epub 2011 Jan 12.

15.

Physical function improvements and relief from fatigue and pain are associated with increased productivity at work and at home in rheumatoid arthritis patients treated with certolizumab pegol.

Hazes JM, Taylor P, Strand V, Purcaru O, Coteur G, Mease P.

Rheumatology (Oxford). 2010 Oct;49(10):1900-10. doi: 10.1093/rheumatology/keq109. Epub 2010 Jun 14.

16.

Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial.

Strand V, Mease P, Burmester GR, Nikaï E, Coteur G, van Vollenhoven R, Combe B, Keystone EC, Kavanaugh A.

Arthritis Res Ther. 2009;11(6):R170. doi: 10.1186/ar2859. Epub 2009 Nov 12.

17.

Clinically meaningful improvement in health-related quality of life in a randomized controlled trial of certolizumab pegol maintenance therapy for Crohn's disease.

Feagan BG, Coteur G, Tan S, Keininger DL, Schreiber S.

Am J Gastroenterol. 2009 Aug;104(8):1976-83. doi: 10.1038/ajg.2009.199. Epub 2009 May 26.

PMID:
19471252
18.

Evaluation of the meaningfulness of health-related quality of life improvements as assessed by the SF-36 and the EQ-5D VAS in patients with active Crohn's disease.

Coteur G, Feagan B, Keininger DL, Kosinski M.

Aliment Pharmacol Ther. 2009 May 1;29(9):1032-41. doi: 10.1111/j.1365-2036.2009.03966.x.

19.

Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study.

Fleischmann R, Vencovsky J, van Vollenhoven RF, Borenstein D, Box J, Coteur G, Goel N, Brezinschek HP, Innes A, Strand V.

Ann Rheum Dis. 2009 Jun;68(6):805-11. doi: 10.1136/ard.2008.099291. Epub 2008 Nov 17.

20.

Effects of the Erika oil spill on the common starfish Asterias rubens, evaluated by field and laboratory studies.

Joly-Turquin G, Dubois P, Coteur G, Danis B, Leyzour S, Le Menach K, Budzinski H, Guillou M.

Arch Environ Contam Toxicol. 2009 Feb;56(2):209-20. doi: 10.1007/s00244-008-9176-8. Epub 2008 May 6.

PMID:
18458993
21.

Peptidoglycan recognition proteins with amidase activity in early deuterostomes (Echinodermata).

Coteur G, Mellroth P, De Lefortery C, Gillan D, Dubois P, Communi D, Steiner H.

Dev Comp Immunol. 2007;31(8):790-804. Epub 2006 Dec 14.

PMID:
17240448
22.
23.

Bioaccumulation and effects of PCBs and heavy metals in sea stars (Asterias rubens, L.) from the North Sea: a small scale perspective.

Danis B, Wantier P, Flammang R, Pernet P, Chambost-Manciet Y, Coteur G, Warnau M, Dubois P.

Sci Total Environ. 2006 Mar 1;356(1-3):275-89. Epub 2005 Aug 1.

PMID:
16055170
24.

Increased phagocytic activity in contaminated seastars (Asterias rubens) collected in the Southern Bight of the North Sea.

Coteur G, Danis B, Wantier P, Pernet P, Dubois P.

Mar Pollut Bull. 2005 Nov;50(11):1295-302. Epub 2005 Jun 8.

PMID:
15946704
25.

Alteration of cellular immune responses in the seastar Asterias rubens following dietary exposure to cadmium.

Coteur G, Gillan D, Pernet P, Dubois P.

Aquat Toxicol. 2005 Jul 30;73(4):418-21.

PMID:
15908022
26.

Measurement of EROD activity: caution on spectral properties of standards used.

Radenac G, Coteur G, Danis B, Dubois P, Warnau M.

Mar Biotechnol (NY). 2004 Jul-Aug;6(4):307-11. Epub 2004 Jul 30.

PMID:
15546046
27.

Interaction of metals with peroxidase--mediated luminol-enhanced, chemiluminescence (PLmCL).

Coteur G, Dubois P.

Luminescence. 2004 Sep-Oct;19(5):283-6.

PMID:
15449349
28.

Environmental factors influencing the immune responses of the common European starfish (Asterias rubens).

Coteur G, Corriere N, Dubois P.

Fish Shellfish Immunol. 2004 Jan;16(1):51-63.

PMID:
14675833
29.

Echinoderms as bioindicators, bioassays, and impact assessment tools of sediment-associated metals and PCBs in the North Sea.

Coteur G, Gosselin P, Wantier P, Chambost-Manciet Y, Danis B, Pernet P, Warnau M, Dubois P.

Arch Environ Contam Toxicol. 2003 Aug;45(2):190-202.

PMID:
14565576
30.

Field contamination of the starfish Asterias rubens by metals. Part 2: Effects on cellular immunity.

Coteur G, Gillan D, Joly G, Pernet P, Dubois P.

Environ Toxicol Chem. 2003 Sep;22(9):2145-51.

PMID:
12959543
31.

Field contamination of the starfish Asterias rubens by metals. Part 1: Short- and long-term accumulation along a pollution gradient.

Coteur G, Pernet P, Gillan D, Joly G, Maage A, Dubois P.

Environ Toxicol Chem. 2003 Sep;22(9):2136-44.

PMID:
12959542
32.

Differentiation of immune cells challenged by bacteria in the common European starfish, Asterias rubens (Echinodermata).

Coteur G, DeBecker G, Warnau M, Jangoux M, Dubois P.

Eur J Cell Biol. 2002 Jul;81(7):413-8.

PMID:
12160149
33.

Reactive oxygen species (ROS) production by amoebocytes of Asterias rubens (Echinodermata).

Coteur G, Warnau M, Jangoux M, Dubois P.

Fish Shellfish Immunol. 2002 Mar;12(3):187-200.

PMID:
11931015
34.

Effects of PCBs on reactive oxygen species (ROS) production by the immune cells of Paracentrotus lividus (Echinodermata).

Coteur G, Danis B, Fowler SW, Teyssié JL, Dubois P, Warnau M.

Mar Pollut Bull. 2001 Aug;42(8):667-72.

PMID:
11525284

Supplemental Content

Loading ...
Support Center